Angiotensin II type 2 receptor in chronic kidney disease: the good side of angiotensin II?  Karen A. Griffin, Anil K. Bidani  Kidney International  Volume 75, Issue 10, Pages 1006-1008 (May 2009) DOI: 10.1038/ki.2009.59 Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 1 Blood pressure and angiotensin-mediated pathways of CKD progression. The deleterious pathways are indicated by solid lines, whereas pathways with potential beneficial effects are indicated by broken lines. A question mark indicates that the evidence is still controversial. The cellular and molecular mechanisms responsible for the compensatory adaptations, including renal vasodilation and glomerular hypertrophy and their regulation, have not as yet been defined. Similarly, the mechanisms responsible for the afferent arteriole autoregulatory impairment after approximately three-quarters of functional renal mass loss remain to be established. GC, glomerular capillary; NO, nitric oxide; RA, afferent resistance; RE, efferent resistance. Kidney International 2009 75, 1006-1008DOI: (10.1038/ki.2009.59) Copyright © 2009 International Society of Nephrology Terms and Conditions